Abstract | OBJECTIVE: To retrospectively estimate the efficacy of various treatments used in men with metastatic penile cancer that progresses after first-line chemotherapy. METHODS: RESULTS: Seventeen had received ≥ 1 salvage therapies; their median survival from first treatment failure was 5.7 months (range, 1.4-30.3 months). Four patients underwent salvage surgery, all of whom experienced further disease progression within 2 months. Four patients received chemoradiotherapy, 1 with stable disease for 13.5 months and 3 with no apparent benefit. Two of 5 evaluable patients (40%) who had received bleomycin, methotrexate, and cisplatin had objective responses (1 complete, 1 partial) but 1 developed fatal pneumonitis. There were no other documented responses to systemic therapy. Median overall survival was 5.6 months for patients who had received a second cisplatin-based treatment at any time and 4.3 months for those who had not (P = .4). CONCLUSION: Patients whose metastatic penile carcinoma progresses through or recurs after front-line cisplatin-based chemotherapy experience poor responses to the described salvage treatments, with a median overall survival time of <6 months. Emphasis should be placed on clinical trials for development of effective therapy in this setting.
|
Authors | Jennifer Wang, Curtis A Pettaway, Lance C Pagliaro |
Journal | Urology
(Urology)
Vol. 85
Issue 5
Pg. 1104-1110
(May 2015)
ISSN: 1527-9995 [Electronic] United States |
PMID | 25819619
(Publication Type: Evaluation Study, Journal Article)
|
Copyright | Copyright © 2015. Published by Elsevier Inc. |
Chemical References |
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Squamous Cell
(mortality, secondary, therapy)
- Chemotherapy, Adjuvant
- Combined Modality Therapy
- Humans
- Male
- Middle Aged
- Neoadjuvant Therapy
- Penile Neoplasms
(drug therapy, mortality, pathology, therapy)
- Retrospective Studies
- Salvage Therapy
- Survival Rate
- Treatment Failure
- Treatment Outcome
- Young Adult
|